Development of a chimeric enediyne targeting tumor-associated proteins shows selective degradation properties, implying possible therapeutic applications.
Protein-radical-oxidation targeting enediyne chimera (PROTEC) comprising an enediyne warhead and a protein-targeting moiety was developed for the selective degradation of tumor-associated protein. PROTEC operates by forming a binary complex with...
No takes yet. Share an insight, caveat, or question.
Pu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: